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ABSTRACT
Introduction: Iodine is an essential micronutrient
and component of the thyroid hormones. Sufficient
ingestion of iodine is necessary for normal growth
and development. If iodine requirements are not met,
growth can be impaired. Salt iodisation and
supplementation with iodine can prevent iodine
deficiency disorders and stunted growth. No
systematic review has yet collated the evidence linking
iodine to growth. With an increased emphasis on
stunting within the WHO Global Nutrition Targets for
2025, we propose a systematic review to address this
question.
Methods and analysis: We will undertake a
systematic review, and if appropriate, meta-analyses,
evaluating the effects of iodised salt or iodine
supplements on prenatal and postnatal somatic
growth, until age 18. We will search a number of
databases, including MEDLINE, EMBASE, Web of
Science, CINAHL, PsychINFO, the Cochrane Library,
including the CENTRAL register of Controlled Trials
and also the WHO library and ICTRP (International
Clinical Trials Registry Platform), which includes the
Clinicaltrials.gov repository. We will also search
Wanfang Data and the China Knowledge Resource
Integrated Database. Included studies must have
compared exposure to iodised salt, iodine
supplements or iodised oil, to placebo, non-iodised
salt or no intervention. Primary outcomes will be
continuous and categorical markers of prenatal and
postnatal somatic growth. Secondary outcomes will
cover further measures of growth, including growth
rates and indirect markers of growth such as insulin-
like growth factor-1 (IGF-1).
Ethics and dissemination: The systematic review
will be published in a peer-reviewed journal, and will
be sent directly to the WHO, United Nations
Children’s Fund, International Council for the Control
of Iodine Deficiency Disorders and other
stakeholders. The results generated from this
systematic review will provide evidence to support
future programme recommendations regarding
iodine fortification or supplementation and child
growth.
Trial registration number: PROSPERO
CRD42014012940.
INTRODUCTION
Micronutrient deﬁciencies are important con-
tributors to the global burden of disease and
Strengths and limitations of this study
▪ This will be the first systematic review to investi-
gate the effects of all forms of iodine supple-
mentation or fortification on somatic growth, in
the relevant population groups.
▪ A great deal of research on iodine nutrition has
been conducted in specific provinces in China. To
ensure that we are comprehensive and capture all
relevant data, we will search Chinese biblio-
graphic databases in addition to the large English
(or other Latin alphabets) bibliographic databases
such as MEDLINE and EMBASE.
▪ This systematic review addresses a high-priority
problem (ie, the prevention and treatment of
stunting) in the field of child and maternal health
and nutrition. The results are potentially useful to
inform iodine-related guidelines and recommen-
dations made by key stakeholders involved in
improving child and maternal health outcomes.
▪ This protocol has been written following the
PRISMA-P guidelines recently developed by the
PRISMA Group,1 2 and we will conduct this sys-
tematic review in line with the rigorous Cochrane
methodology. Our international, expert review
team brings both subject and methods expertise to
the project. Given that much of the significant
research contributions in the field of iodine nutri-
tion are older, and that randomised trials are often
not available to assess the effects of iodine-related
fortification and supplementation interventions, we
will include a broader range of non-randomised
study designs to fully evaluate the current available
evidence for our question. While non-randomised
studies may provide valuable evidence on the
effects of interventions, their inclusion introduces
a greater risk of bias, specifically systematic selec-
tion bias, which can give rise to confounding
threatening internal validity. Risk of bias and
quality of evidence assessments (GRADE) will be
carefully considered when interpreting data, report-
ing findings and formulating conclusions.
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disability3 One of the most widespread micronutrient
deﬁciencies worldwide is that of iodine. The WHO esti-
mates that approximately 285 million, or 37% of school-
age children and nearly two billion individuals worldwide
have insufﬁcient iodine intake.4
Iodine is required for normal physical growth during ges-
tation and early life, and it is an essential component of the
hormones produced by the thyroid gland. When dietary
iodine requirements are not met, synthesis of the thyroid
hormones is impaired. The resulting hypothyroidism
induced by iodine deﬁciency during pregnancy, infancy
and childhood can impair growth and development.5–8
The reduced activity of thyroid hormones resulting from
iodine deﬁciency, reduces the effects of growth hormone
(either through effects on pituitary secretion or at its recep-
tor) and as well as circulating concentrations of insulin-like
growth factor (IGF-1) and its binding proteins.9 10 Iodine
deﬁciency can result in a number of developmental and
functional abnormalities, the spectrum of which is referred
to as the iodine deﬁciency disorders (IDD).6 9
Salt iodisation has been recommended as a safe and
cost-effective primary strategy to ensure sufﬁcient iodine
intake by all individuals, including pregnant women and
children.6 In situations where the coverage of iodised salt
is incomplete, daily iodine supplementation is recom-
mended to pregnant women, lactating women and
infants.6 Periodic doses of iodised oil may also be an
effective intervention in vulnerable groups until iodised
salt can be implemented.6 Iodine may also be provided
through fortiﬁcation of certain foodstuffs, including milk
and bread and water.
There is an increased emphasis on stunting on
the global nutrition agenda, and stunting will likely
be a leading post-Millennium Development Goal.11 12
Consequently, the roles of nutrition interventions, includ-
ing micronutrient strategies for stunting have recently
received attention from global decision-makers, such as
the WHO. There is a need to examine this evidence
base13 in line with recent efforts to promote evidence-
informed guideline development for nutrition.14 Within
this context, the evidence on the role of iodine in pre-
natal and postnatal growth has not received much focus
to date. The prevention and correction of iodine deﬁ-
ciency may be an important contributor to reducing
stunting, as part of a multiple intervention package for
improving child health.
To avoid duplication and investigate the need for a new
systematic review on this question, we ﬁrst conducted at
scoping review,15 and identiﬁed 10 existing systematic
reviews,16–25 that investigate the effect of iodine supplemen-
tation on cognitive development, thyroid function, iodine
deﬁciency disorders and certain growth outcomes in chil-
dren and adults. None of the identiﬁed systematic reviews
investigated the effects of all forms of iodine fortiﬁcation/
supplementation in all of the relevant population groups
(ie, women of childbearing age, pregnant and lactating
women and children of all ages) on all of the relevant
growth and growth-related outcomes.
A previous Cochrane systematic review published in
2002,23 concluded that iodised salt was an effective means
of improving population iodine status and found no
adverse effects of iodine supplementation or fortiﬁcation.
However, there was insufﬁcient evidence to make conclu-
sions regarding outcomes, such as childhood growth or
cognition. Since the review in 2002, many additional
studies have been published which may provide informa-
tion on these developmental outcomes. A recent update of
the above Cochrane Review,26 included studies investigat-
ing the effect of iodised salt only, in children and adults on
outcomes including all-cause mortality, goitre, cognitive
function and cretinism. The update did not examine the
effects of all forms of iodine supplementation on foetal or
infant growth, either prenatal or postnatal.
Iodine deﬁciency has been and remains a major
problem in certain regions of China, such as the Gansu,
Yunnan and Sichuan provinces. There has been much
research aimed at improving iodine nutrition in these
areas and elsewhere in China, which represents an
important component of iodine literature worldwide.
Iodine intervention studies undertaken in China may
not have been captured in previous systematic reviews
published in English or other Latin alphabets, or in
reviews where searches were not undertaken speciﬁcally
in Chinese databases: our scoping review,15 found that
Chinese databases had been speciﬁcally searched in only
2 of the 10 systematic reviews identiﬁed.
Data from both observational and experimental studies
have described the relationship between iodine nutrition
and somatic growth,7 10 27–29 however this literature has
never been systematically evaluated with respect to this spe-
ciﬁc question. A systematic review of studies investigating
the effects of all forms of iodine supplementation and for-
tiﬁcation on prenatal and postnatal somatic growth in rele-
vant population groups is clearly required to interpret the
existing body of evidence addressing this question, and
possibly identify gaps for future research. The objective of
this systematic review is therefore to assess the effects of
iodised salt, iodine supplements and iodised oil compared
to placebo or no intervention on somatic growth of the
fetus, infant and child, and deﬁne the magnitude of the
effect on growth after iodine repletion.
METHODS AND ANALYSIS
In line with Cochrane recommendations, our review
team includes both subject experts and researchers with
expertise in systematic review methodology.30 One core
review team (CEN, LN and JF) will be responsible for
the review of literature in English and other Latin alpha-
bet texts. Two Chinese reviewers also proﬁcient in
English (ZS and ZY) will comprise another core review
team, being speciﬁcally responsible for all literature in
Chinese. A common, standardised work plan has been
established to streamline all processes within both
groups, which will be led by one reviewer ( JF). An advis-
ory group consisting of the three senior authors and a
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senior methods expert will guide the process. A consult-
ant biostatistician has reviewed the protocol and relevant
additional statistical expertise will be sought, as needed.
The review will be performed following Cochrane meth-
odology.30 31 The PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses)32 statement
will be used for the reporting of the review.
We formulated the following research question: “What
are the effects of iodised salt, iodised oil or iodine sup-
plements compared to placebo or no iodine interven-
tion on prenatal and postnatal somatic growth of the
foetus, infant, child and adolescent?”
Our systematic review is registered with PROSPERO,
registration number CRD42014012940, available at
http://www.crd.york.ac.uk/PROSPERO.
Criteria for considering studies for inclusion
Types of studies
We will include randomised controlled trials (RCTs), and
non-randomised controlled trials (non-RCTs), controlled
before-after (CBA) studies, interrupted time-series
studies (ITS) and interrupted time series studies with
repeated measures (RMS).33 All studies must have com-
pared a group of individuals with exposure to iodised
salt, iodine supplements or iodised oil to a group receiv-
ing a placebo, non-iodised salt or no intervention. In the
case of ITS and RMS studies, observations at multiple
time points before and after an intervention must be
included in the study design. ITS and RMS that do not
have a clearly deﬁned point in time when the interven-
tion occurred and at least three data points before and
three after the intervention will be excluded, as multiple
data points are required to detect whether the interven-
tion has had an effect signiﬁcantly greater than any
underlying trend over time. Trials can be of a parallel or
crossover design. For crossover studies the data from the
ﬁrst period must be available.
Types of participants
For prenatal growth, the populations will be pregnant
women or women of childbearing age, and their off-
spring. For postnatal growth, the participants will be lac-
tating women and their breastfeeding infant considered
as one unit, in addition to children of any age (0–18
years) and of either gender. Study populations could be
within the general population or part of speciﬁc popula-
tions such as refugee populations. Studies looking specif-
ically at the link between growth and populations
affected by congenital hypothyroidism and goitre will be
excluded. Similarly, studies looking at non-iodine-related
growth will be excluded. Furthermore, studies reporting
on pregnant women who smoke will be excluded, since a
correct assessment of the effects of iodine on growth in
this population cannot be adequately assessed.
Types of interventions and comparisons
This review will consider exposure to iodised salt, iodine
supplementation or iodised oil in any form, dose and
regimen (including multinutrient interventions) com-
pared to a placebo, non-iodised salt or no intervention.
The populations being compared should have a similar
baseline iodine status, for example, being from the same
geographical area with a known iodine status, and they
must be comparable. Comparisons featuring populations
that are from areas with a different baseline iodine
status, that is, from an area of known deﬁciency in com-
parison to a region of established excess, will be
excluded. Multinutrient interventions where the effect
of iodine alone cannot be assessed will be excluded.
Types of outcomes
We will include studies that adhere to the descriptions
above and that report any of the following outcomes:
Primary outcomes:
▸ Prenatal somatic growth (measured, eg, using birth
weight and birth weight indices (such as intrauterine
growth restriction, small-for-gestational age low birth-
weight, ponderal index), head circumference), in
addition to in utero ultrasound measurements such as
biparietal diameter) and measurements made during
pregnancy, for example symphysis-fundal height.
▸ Postnatal somatic growth (measured, eg, using anthro-
pometry (head circumference, weight-for-age, height
or length-for-age, weight-for-height, BMI-for-age, mid-
upper arm circumference, child growth rate)).
Secondary outcomes:
▸ Cretinism;
▸ Pregnancy weight gain;
▸ Indirect markers of somatic growth (insulin-like
growth factor (IGF)-1; insulin-like growth factor
binding protein (IGFBP)-3, Growth Hormone);
▸ Postnatal bone maturation;
▸ Malnutrition disorders (kwashiorkor, marasmus).
Search methods for identification of studies
Electronic searches
A comprehensive search strategy was compiled in con-
sultation with an expert librarian skilled in systematic
review searching (see appendix). Using no date or lan-
guage restrictions, the librarian will use the search strat-
egy to search the following databases:
▸ MEDLINE
▸ EMBASE
▸ WEB OF SCIENCE (Social Sciences Citation index/
Science Citation Index)
▸ Cochrane Library, including CENTRAL register of
Controlled Trials
▸ CINAHL (Cumulative Index to Nursing and Allied
Health Literature)
▸ WHO International Clinical Trials Registry Platform
(ICTRP; which includes http://www.clinicaltrials.gov)
for on-going studies
▸ WHO library
▸ PsycINFO
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The search terms will be translated into Chinese, and
we will search the following databases for records in
Chinese, with no date restrictions:
▸ China Knowledge Resource Integrated Database
(http://www.cnki.net), which includes the databases:
– China Academic Journals Full-text Database
– China Doctoral Dissertations Full-text Database
– China Masters Theses Full-text Database
– China proceedings of Conferences Full-text Database
– International Proceedings of Conferences Full-text
Database
▸ Wanfang Data (http://www.wanfangdata.com), which
includes the databases:
– China Online Journals
– Dissertations of China.
Searching other resources
For assistance in identifying ongoing or unpublished
studies, we will contact the Sprinkles Global Health
Initiative, the In-Home Fortiﬁcation Technical Advisory
Group, the nutrition section of the United Nations
Children’s Fund (UNICEF), the World Food Programme
(WFP), the Micronutrient Initiative (MI), the Global
Alliance for Improved Nutrition (GAIN), Helen Keller
International (HKI), Sight and Life Foundation, the
Department of Nutrition for Health and Development,
WHO, the US Centers for Disease Control and Prevention
(CDC) and the International Council for the Control of
Iodine Deﬁciency Disorders (ICCIDD) Global Network.
We will contact experts in the ﬁeld of iodine nutrition
concerning studies published in non-peer-reviewed lit-
erature for example, book chapters. We will search the
reference lists of the systematic reviews included in our
scoping review,15 and any other existing systematic
reviews identiﬁed during screening for eligible studies.
Additionally, we will search the Chinese literature within
the repository of full-text studies yielded from searches
for a previous similar systematic review.26
Data collection and analysis
Selection of studies
Two reviewers from each core review team will inde-
pendently screen the titles and abstracts of all records
yielded by the respective searches. The reviewers from
both teams will apply the prespeciﬁed criteria to identify
potentially eligible studies for inclusion.
Full-texts articles of all potentially eligible studies iden-
tiﬁed by either of the reviewers will be retrieved for closer
inspection. Full texts that are excluded after closer
inspection will be listed in the table ‘Characteristics of
Excluded Studies’, together with the reasons for their
exclusion. The Covidence software platform,34 will be
used to facilitate independent screening and selection,
and to identify screening and inclusion discrepancies.
Any discrepancies not resolved within each core review
team, will be resolved through discussion with the other
core review team and the advisory group.
Data extraction and management
Two reviewers from each core review team will inde-
pendently extract relevant data from all eligible studies
using a standardised data extraction form based on a
good practice data extraction form for systematic
reviews.35 Discrepancies regarding extracted data will be
resolved as before, by discussion with the other core
review team and advisory group, as necessary. All data
not presented in English will be translated.
The following will be extracted from each included study:
▸ Administrative details: Trial identiﬁcation number;
author(s); published or unpublished; year of publica-
tion; number of studies included in paper; year in
which study was conducted; details of other relevant
papers cited;
▸ Details of the study: study design (eg, RCT, CBA, ITSS);
type, duration and completeness of follow-up; country
and location of study (eg, higher-income vs lower-
income country); representativity (eg, local, regional or
national level), informed consent and ethics approval;
▸ Details of participants: age, sex, sample size, relevant
baseline characteristics including iodine status (UIC)
and thyroid hormone concentrations (Tg, TSH, T4,
T3); prevalence of hypothyroidism, hypothyroxine-
mia, hyperthyroidism;
▸ Details of intervention and control group: type (iodate/
iodide) and level of iodine fortiﬁcation, type of
iodine supplements, dosage of supplement, form and
formulation of supplement, additional cointerven-
tions (such as fortiﬁcation with micronutrients); treat-
ment received by the control group.
▸ Details of outcomes: all prespeciﬁed outcomes and any
additional outcomes reported in the study, adverse
events and toxicity.
▸ Details of quality assessment: quality assessment of the
study based on the Risk of Bias tool.
▸ Details of data analysis: numbers and reported statistics
for each reported outcome.
Where trials are reported in more than one reference,
relevant data from all trial reports will be extracted as
comprehensively as possible, and the most recent effect
sizes used in analyses, as appropriate. The Covidence soft-
ware platform,34 will be used to compare double data
extraction online. Where relevant, data from Covidence
will be exported into Review Manager 5.1 for analysis.36
Assessment of risk of bias in included studies
Two reviewers from each core review team will independ-
ently assess the risk of bias of each included study using
the EPOC Risk of Bias criteria for RCTs, non-RCTs, CBA
studies and ITS.37 The Covidence software platform,34 will
be used to compare methodological quality assessment
and discrepancies resolved through discussion and con-
sultation with the advisory group.
Measures of treatment effect
For dichotomous outcomes, where possible, the risk ratio
(RR) from statistical analyses, adjusting for baseline
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differences (such as Poisson regressions or logistic regres-
sions), or the ratio of RRs (ie, the RR postintervention/
RR preintervention) will be calculated using Review
Manager 5.1.36 38 For continuous variables, if possible,
the weighted mean difference (WMD) with 95% CIs, the
absolute change from a statistical analysis adjusting for
baseline differences (such as regression models, mixed
models or hierarchical models) or the relative change
adjusted for baseline differences in the outcome mea-
sures (ie, the absolute postintervention difference
between the intervention and control groups—the abso-
lute preintervention difference between the intervention
and control groups)/the postintervention level in the
control group) will be calculated by meta-analysis. If
necessary, standardisation of continuous outcomes across
studies will be performed prior to meta-analysis (eg, as
standardised mean differences).38 Statistical expertise will
be sought for conducting meta-analysis of standardised
outcomes, and for all other complex analyses, if required.
For ITS and RMS we will use either a regression ana-
lysis with time trends before and after the intervention,
adjusting for autocorrelation and any periodic changes,
or the ARIMA (autoregressive integrated moving
average) analysis, which is used in time series analyses to
understand or predict future trends. Where possible, the
results for the outcomes will be presented as changes
along two dimensions, namely change in level and
change in slope. For ITS and RMS that do not deﬁne a
transition phase, a transition phase will be deﬁned and
transition phase data will be excluded.38 If papers with
ITS design do not provide an appropriate analysis or
reporting of results, but present the data points in a
table or in a graph that can be scanned, wherever pos-
sible, we will reanalyse the data using methods described
in Ramsay et al.39
In RMS, the data are repeated outcome measures
from many individuals. If a study does not report appro-
priate results, we will not reanalyse the data from the
summary graphs, because no estimate of within-patient
variability can be obtained from the summary graphs
and any reanalysis would underestimate or overestimate
the SE of the effect sizes. Therefore, we will only present
the results reported in the original papers.38
Unit of analysis errors
For clustered designs (such as cluster randomised trials)
the reported results in included studies will often be on
another level than the level of allocation. If this is the
case, an analysis adjusting for clustering will be per-
formed in order to avoid unit-of-analyses errors. When
extracted results are not based on analyses adjusted for
clustering, a re-analysis of the results will be conducted.
If there is a unit of analysis error in the reported analysis
for a study and there is insufﬁcient information to
re-analyse the results, the study authors will be contacted
to obtain necessary data. If these data are not available,
we will not report CIs or p values for which there is a
unit of analysis error.38
Dealing with missing data
Where data is missing or unclear, we will contact study
authors wherever possible. When percentages were pro-
vided without denominators we will back-calculate to
determine denominators. If only SEs or 95% CIs are
reported for means and no SDs, the SDs will be calcu-
lated as follows: SD=SEM×Square root of sample size. If
unable to obtain missing data, we will report the results
that are available, provided they are not likely to be mis-
leading (eg, if there is a unit of analysis error).38
Assessment of heterogeneity
Studies will ﬁrst be assessed for clinical heterogeneity by
examining variability in the participants, interventions and
outcomes. Where it is clinically meaningful to combine
studies, we will conduct a meta-analysis using random-
effects model as we anticipate heterogeneity. We will
further assess statistical heterogeneity in the meta-analysis
study results using the χ2 test for heterogeneity (signiﬁ-
cance level p<0.1). Statistical heterogeneity will also be
quantiﬁed with the I2 test, using the following guidelines
for the interpretation of the I2 values:40 0–40%: might not
be important; 30–60%: may represent moderate hetero-
geneity; 50–90%: may represent substantial heterogeneity
and 75–100%: considerable heterogeneity.
Assessment of reporting biases
Provided there are a sufﬁcient number of studies we will
use a funnel plot to assess the risk of publication bias.
Data synthesis and investigation of heterogeneity
Where studies are sufﬁciently homogenous the results of
each of the prespeciﬁed outcomes reported in the studies
will be combined using random-effects meta-analysis.
When data allow, the intervention effects across the
following subgroups (explanatory factors) will be com-
pared to explore heterogeneity:
▸ Iodised salt versus iodine supplements (eg, iodised oil)
▸ Age: prenatal (birth weight); infant (0–24 months);
preschool child (2–5 years), school age child (6–12
years) and adolescent (13–18 years).
These subgroups are selected following conventional
classiﬁcations based on growth periods. Across all modes
of iodine intake being investigated, with the exception
of iodised oil, we expect a positive inﬂuence of iodine
on growth equally across all age groups, thereby consid-
ering the bioavailability of iodine from salt, supplement,
milk, bread or water to be equivalent. For iodised oil,
the age subgroups become particularly important, as we
expect the positive effect of iodine on growth to increase
with age. This is due to the fact that individuals in older
age groups will be more developed physically, including
having a higher proportion of adipose tissue. Since
iodised oil is stored in adipocytes,41 it follows that a
greater proportion of a given iodised oil dose will be
absorbed, thereby providing a more important store of
iodine for a more prolonged release.
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If there are sufﬁcient numbers of comparisons
for similar outcomes across studies, we will use graph-
ical displays (bubble and whisker plots) to visually
explore heterogeneity of the results across studies. If
appropriate, the visual analyses will be supplemented
with multivariate statistical analyses (meta-regression),
to examine how the size of observed effects is related
to the speciﬁed subgroups (explanatory factors).38
Several methods for performing meta-regression
exist and statistical expertise will be sought for select-
ing the most appropriate method and software.
Sensitivity analysis
To determine how robust and consistent the results are,
sensitivity analyses will be conducted based on study
design (RCT vs other) or risk of bias in study (high,
medium, low risk of bias). If a number of eligible trials
investigate the effect of iodine in combination with
multinutrient interventions (fortiﬁcation and supple-
mentation) compared with multinutrient interventions
alone, then a sensitivity analysis will be performed to
assess the combined effect of iodine and multinutrient
interventions versus iodine supplementation or fortiﬁca-
tion alone. In the event of missing data, we will
perform sensitivity analyses for missing data by imput-
ing a plausible range of assumptions. The potential
implications of missing information will be discussed. In
addition, any methodological decisions (eg, choice of
intra cluster coefﬁcient (ICC) for re-analysis of cluster
randomised trials or inclusion/exclusion of studies
from analyses based on prespeciﬁed criteria such
dropout rates >20%) taken in the course of preparing
the review will be checked for stability of results in a
sensitivity analysis.38
Quality of evidence using GRADE
Quality of evidence will be assessed using Grading of
Recommendations, Assessment, Development and
Evaluation (GRADE), via the GRADEpro browser-based
platform (http://www.gradepro.org last accessed 12
November 2014)42 will be used to create Summary of
Findings tables for each comparison using the pre-
peciﬁed outcomes. In determining the level of evidence
for each outcome, both the efﬁcacy results and the
assessment of the risk of bias will be integrated into a
ﬁnal assessment of the level of evidence and details of
the decision will be provided.
Current study status
At time of submission, we are in the process of screening
full texts for the review, and expect to start data extrac-
tion in April 2015. Study details will be continuously
updated on PROSPERO, and any amendments made
will be fully published there with the date of amend-
ment and full rationale.
DISCUSSION
Our systematic review will aim to provide a comprehen-
sive, systematic assessment of existing evidence on the
effects of iodine, in the form of salt or supplement, on
somatic growth outcomes, both prenatal and postnatal
to the age of 18 years. It will also provide an evaluation
of the quality of this evidence using GRADE.42 The
results will be interpreted and presented using Summary
of Findings tables that reﬂect both the magnitude of
effect and conﬁdence in that effect. Consequently, these
tables provide concise summaries of the key information
needed in the decision-making process and, in the
context of guideline development, provide summaries of
the key information underlying a recommendation.43
Thus, it is hoped that this review will address an identi-
ﬁed gap in the evidence and support future recommen-
dations and programme guidance regarding iodine
fortiﬁcation and supplementation, and child growth and
health. We envision that the results will be particularly
useful to the WHO and other international organisa-
tions working towards achieving the 2025 WHO Global
Nutrition Targets.
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